Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Sutro Biopharma's total debt was $4.06M at Dec 31, 2023. For fiscal 2023 it was $4.06M, down 75.0% from the year before. The highest annual figure on record is $25.11M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.06M | -75.0% |
| FY2022 | Dec 31, 2022 | $16.27M | -35.2% |
| FY2021 | Dec 31, 2021 | $25.11M | +2.3% |
| FY2020 | Dec 31, 2020 | $24.55M | +148.5% |
| FY2019 | Dec 31, 2019 | $9.88M | -32.9% |
| FY2018 | Dec 31, 2018 | $14.72M | +1.1% |
| FY2017 | Dec 31, 2017 | $14.56M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $4.06M | -75.0% |
| Q3 FY2023 | Sep 30, 2023 | $7.14M | -63.0% |
| Q2 FY2023 | Jun 30, 2023 | $10.20M | -54.2% |
| Q1 FY2023 | Mar 31, 2023 | $13.24M | -47.6% |
| Q4 FY2022 | Dec 31, 2022 | $16.27M | -35.2% |
| Q3 FY2022 | Sep 30, 2022 | $19.28M | -22.8% |
| Q2 FY2022 | Jun 30, 2022 | $22.28M | -10.2% |
| Q1 FY2022 | Mar 31, 2022 | $25.26M | +2.4% |
| Q4 FY2021 | Dec 31, 2021 | $25.11M | +2.3% |
| Q3 FY2021 | Sep 30, 2021 | $24.96M | +2.3% |
| Q2 FY2021 | Jun 30, 2021 | $24.82M | +2.2% |
| Q1 FY2021 | Mar 31, 2021 | $24.68M | +2.2% |
| Q4 FY2020 | Dec 31, 2020 | $24.55M | +148.5% |
| Q3 FY2020 | Sep 30, 2020 | $24.41M | +115.2% |
| Q2 FY2020 | Jun 30, 2020 | $24.28M | +89.6% |
| Q1 FY2020 | Mar 31, 2020 | $24.16M | +69.3% |
| Q4 FY2019 | Dec 31, 2019 | $9.88M | -32.9% |
| Q3 FY2019 | Sep 30, 2019 | $11.34M | -22.7% |
| Q2 FY2019 | Jun 30, 2019 | $12.81M | -12.1% |
| Q1 FY2019 | Mar 31, 2019 | $14.27M | – |
| Q4 FY2018 | Dec 31, 2018 | $14.72M | – |
| Q3 FY2018 | Sep 30, 2018 | $14.68M | – |
| Q4 FY2017 | Dec 31, 2017 | $14.56M | – |
See a number that looks wrong?